Zoetis is expected to outperform low market expectations for Q3 and Q4, with consensus and management forecasting declines in revenue and earnings per share. However, the company's diverse growth drivers, including expanding parasite prevention products, steady livestock sales, and a growing diagnostics segment, suggest these forecasts could be surpassed. If Zoetis meets or exceeds Q3 targets, it may trigger a sustained stock rally and renewed investor confidence in this quality growth company. This outlook follows a period of underperformance but highlights Zoetis's potential in the pet health sector, which gained prominence during the COVID-19 pandemic due to increased pet ownership.
Zoetis shares are trading at USD 82.72 on Pluang, down 0.33% as of Nov 04, 2026 12:41 WIB. The stock shows strong investor interest with 94% of orders to buy and a dividend yield of 2.55%.
